CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.7%

CytoMed Therapeutics Limited (NASDAQ:GDTC)’s stock price was down 0.7% on Friday . The stock traded as low as $1.45 and last traded at $1.48. Approximately 2,369 shares traded hands during trading, a decline of 94% from the average daily volume of 39,923 shares. The stock had previously closed at $1.49.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 price objective on shares of CytoMed Therapeutics in a research note on Tuesday, June 11th.

CytoMed Therapeutics Price Performance

The company has a current ratio of 14.09, a quick ratio of 14.09 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $1.81 and its two-hundred day moving average is $2.00.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.